United Therapeutics
$541.70Change from previous close: −5.19%Absolute change: −$29.68
At a glance
- Revenue growth
- +10.61%
- 2025 vs 2024
- Net income growth
- +11.68%
- 2025 vs 2024
- Net margin
- 41.9%
- 2024: 41.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 314 | 463 | 346 | 562 | 192 | — |
| Depreciation and amortization | 24.2 | 22.6 | 22.8 | 21.9 | 21.1 | — |
| Capital expenditure | -108 | -101 | -173 | -216 | -62.2 | — |
| Investing cash flow | 87.5 | 744 | -228 | 141 | -300 | — |
| Financing cash flow | 122 | -1,484 | 98.4 | -956 | -199 | — |
| Share repurchases | -58.8 | -1,500 | 4.4 | -1,001 | -20.5 | — |
| Debt issued | — | — | 0.0 | 0.0 | — | — |
| Debt repaid | 0.0 | 0.0 | 0.0 | 0.0 | -400 | — |
| Net change in cash | 524 | -277 | 217 | -253 | -307 | — |
| Free cash flow | 206 | 363 | 173 | 346 | 130 | — |